Gastrointestinal stromal tumors (GISTs) occur in humans, dogs and other species, and are among the most common mesenchymal tumors that originate from the interstitial cells of Cajal in the walls of the gastrointestinal tract \[[@r14], [@r15]\].

The c*-kit* gene encodes the KIT protein, which is a receptor tyrosine kinase that mediates the signaling of stem cell factor (SCF), a cytokine involved in hematopoiesis and mast cell growth \[[@r12]\].Mutations of the c*-kit* gene have been identified in exons 9 (5--10%) and 11 (60--70%) in cases of human GISTs \[[@r1]\]. Studies on human GISTs \[[@r3]\] and canine mast cell tumors (MCTs) \[[@r7]\] have indicated that imatinib mesylate, a tyrosine kinase inhibitor, may be effective in the treatment of these tumors, depending on the presence and location of c*-kit* mutations \[[@r6], [@r9]\]. Furthermore, a previous case study has reported imatinib mesylate to be effective against canine GISTs that contained a mutation in exon 11 of the c*-kit* gene \[[@r9]\]. Cases of canine GISTs with c*-kit* mutations may therefore be clinically responsive to imatinib mesylate treatment \[[@r5], [@r6]\].

Here, we describe a case of canine recurrent GIST harboring a mutation in exon 9 of the c*-kit* gene that responded clinically to the administration of imatinib mesylate.

A 13-year-old, 10-kg, spayed mixed-breed dog with a body condition score of 3/5 and a 1-week history of vomiting and anorexia was referred to the Shikoku Veterinary Medical Center, located in Kagawa Prefecture, Japan. Upon physical examination, we detected a large mass in the abdominal cavity through palpation. Abdominal ultrasonography revealed the mass to be approximately 10 cm in diameter with mixed echogenicity. A fine-needle aspiration of the mass showed clusters of spindle-shaped cells. There were no apparent abnormalities observed in the complete blood cell count, blood chemistry tests or blood coagulation profile.

Abdominal radiography, however, revealed the presence of a single large lesion in the abdominal cavity. Based on computed tomography (CT) findings ([Fig. 1A and 1B](#fig_001){ref-type="fig"}Fig. 1.Preoperative CT images: (A) Transverse image of the 5th lumbar vertebra and (B) sagittal image indicating a large mass with an irregular surface (12 × 8 × 6 cm in size) extending from the cecum. (C) Photograph of the surgically resected area showing the main tumor and multiple disseminated masses (arrows) in the omentum. L5, 5th lumbar vertebra; m, main tumor; s, spleen; b, bladder.), we concluded that the mass originated from the cecum and could be surgically resected. Laparotomy exposed a tumor that was approximately 12 × 8 × 6 cm in size, had an irregular surface and originated from the cecum ([Fig. 1C](#fig_001){ref-type="fig"}). In addition to the large mass, we observed 5 to 10 smaller masses (ranging from 1 mm to 20 mm in diameter) in the omentum. During surgery, the cecum was partially removed, and the omentum with the disseminated tumors was excised.

Histopathological examination of the excised tumor revealed that the mass had unclear boundaries and had originated from the muscle layer of the cecum. The tumor tissue was composed of spindle-form neoplastic cells arranged in streams and interlacing bundles, and was supported by abundant basophilic myxoid stroma. The tumor cells had wispy eosinophilic cytoplasm, as well as ovoid to cigar-shaped nuclei with a single small nucleolus ([Fig. 2A](#fig_002){ref-type="fig"}Fig. 2.(A) Histopathological features of the resected abdominal mass using hematoxylin and eosin stain at 100 × magnification. Tumors were composed of spindle-form neoplastic cells arranged in streams and interlacing bundles and were supported by abundant basophilic myxoid stroma. (B) Histopathological features of the resected abdominal mass using hematoxylin and eosin stain at 400 × magnification. The tumor cells showed wispy eosinophilic cytoplasm, ovoid to cigar-shaped nuclei with a small single nucleolus, and mild to moderate anisocytosis and anisokaryosis. (C) Immunohistochemical analysis of the resected abdominal mass using immunohistochemical staining with anti-KIT antibodies followed by hematoxylin counterstain at 100 × magnification. Most cells were positive for human KIT.). Mild to moderate anisocytosis and anisokaryosis were also observed in the tumor cells. The mitotic index ranged from 0 to 1 mitotic figures per 5 high-power fields ([Fig. 2B](#fig_002){ref-type="fig"}).

Immunohistochemical analysis using an antibody against human KIT (Dako, Carpinteria, CA, U.S.A.) demonstrated that most of the tumor cells were positive for KIT proteins ([Fig. 2C](#fig_002){ref-type="fig"}), and the tumor was therefore identified as GIST. A DNA sample obtained from paraffin-embedded sections of the tumor was subjected to sequence analysis of exon 11 of the c-*kit* gene; however, no mutations were found in the target sequence.

Because several residual tumors were detected in the omentum, 200 mg/m^2^ of carboplatin (Paraplatin; Bristol-Myers Squibb, New York, NY, U.S.A.) was administered to the dog 2 weeks after surgery; the drug was further administered once every 3 weeks for a total of 6 doses. However, a scheduled follow-up examination conducted 160 days after the initial surgery indicated the possible recurrence of GIST in the omentum. CT scans showed the presence of numerous masses with diameters ranging from 2 cm to 5 cm. Exploratory laparotomy revealed multiple tumors up to 5 cm in diameter. As the complete and safe removal of all the tumors was not feasible, only a limited number of masses were resected for biopsy. Histopathological examination of the resected masses confirmed the recurrence of GIST.

Total RNA was extracted from paraffin-embedded tumor tissue resected during the second surgery using an RNeasy FFPE kit (Qiagen, Valencia, CA, U.S.A.), and the corresponding cDNA was synthesized as previously described \[[@r16]\]. The forward primer 5′-GCACAGACACAGAGTAATAGC-3′ and reverse primer 5′-GAAGGCACCAGCACCCAAAGT-3′ were then used to amplify c*-kit* cDNA from the single-strand cDNA through PCR with KOD FX DNA polymerase (Toyobo, Osaka, Japan). The PCR products were sub-cloned into a pCR-Blunt vector (Invitrogen, Carlsbad, CA, U.S.A.), and the sequence of the full length c*-kit* cDNA was obtained using a previously described method \[[@r16]\]. When compared with the wild-type canine c-*kit* gene (GenBank accession no. AY313776), the GIST tissue showed a point mutation in exon 9 (1523A\>T) ([Fig. 3](#fig_003){ref-type="fig"}Fig. 3.Identification of the point mutation in the c-*kit* gene and assembly of wild-type and mutant c*-kit* nucleotide sequences. D1 to D5, immunoglobulin-like domains; TM, transmembrane domain; JM, juxtamembrane domain; TK1, adenosine triphosphate (ATP) binding site; TK2, activation loop.).

Based on the findings of the c*-kit* sequence analysis, we began administration of imatinib mesylate (10 mg/kg q 24 hr) (Veenat; Natco Pharma, Hyderabad, India) 2 weeks after surgery. In an abdominal ultrasonography conducted 2 weeks after the initial imatinib mesylate administration, the lengths of the residual masses in the abdominal cavity were found to have shrunk to less than half of their original lengths. In accordance with the classification criteria for solid tumor response evaluation \[[@r4]\], the observed reduction in tumor size indicated a partial remission (PR). Two months after the initiation of imatinib mesylate treatment, ultrasonography and CT imaging indicated complete remission (CR) of GIST ([Fig. 4](#fig_004){ref-type="fig"}Fig. 4.CT images taken after the recurrence of GIST: (A) Transverse image and (B) frontal image of the abdomen taken 162 days after the initial surgery. The white arrowheads indicate the intraabdominal mass. (C) Transverse image and (D) frontal image of the abdomen taken 1,700 days after the initial surgery. The mass was observed to have completely disappeared in this later stage. s, spleen; rk, right kidney.). Treatment of imatinib mesylate with the same dosage was continued even after achievement of CR to prevent further recurrence. The dog remained in CR with continuous daily administration of imatinib mesylate. Ultrasonography was conducted during periodic health examinations once every 3--6 months.

Although the dog was periodically re-examined at our veterinary medical center, it eventually died of pneumonia 4 years and 5 months after the second surgery. There was no indication of GIST recurrence at the time of the dog's death.

This case did not present with any severe adverse events associated with imatinib mesylate treatment. All of the procedures involved in the examination and treatment of this case were conducted in accordance with the guidelines for small animal practice issued by the Japanese Veterinary Medical Association in 2007.

A mutation within exon 9 of the c*-kit* gene (1523A\>T) was found in the GIST tissue extracted from our canine patient. Although the phosphorylation of the KIT protein was not evaluated in this study, this type of mutation has been observed in 1.5% of canine MCTs \[[@r11]\] and has been shown to cause constitutive phosphorylation of the KIT protein \[[@r17]\].

The c*-kit* point mutation (1523A\>T) observed in this case has yet to be reported in canine GISTs. Kobayashi *et al.* \[[@r9]\] have previously reported a case of canine GIST harboring a c*-kit* mutation in exon 11 that responded to imatinib mesylate treatment \[[@r8]\]; although imatinib mesylate treatment was able to generate a PR response, CR could not be achieved in their canine patient. In contrast, the canine patient described here achieved CR with the same dose of imatinib mesylate (10 mg/kg q 24 hr) and survived for a long period after treatment without relapse. Although a further study is needed to produce definitive results, our findings in conjunction with the report by Kobayashi *et al.* \[[@r9]\] suggest the possible effectiveness of imatinib mesylate for the treatment of GISTs in dogs.

As human GIST patients with exon 9 or exon 11 mutations in the *c-kit* gene have been shown to be responsive to imatinib mesylate treatment \[[@r2]\], this has become the first-choice drug in the treatment of metastatic or recurrent GISTs. However, patients with exon 9 mutations have been reported to have decreased sensitivity to this treatment \[[@r1], [@r3]\]. Therefore, such patients require higher doses of imatinib mesylate, or even treatment with other tyrosine kinase inhibitors, such as sunitinib malate. Despite having an exon 9 c-*kit* mutation, our canine patient demonstrated good response to imatinib mesylate treatment and was able to achieve CR. This apparent discrepancy may be explained in part by the difference in the type of exon 9 mutation between canine (point mutation) and human (duplication) GISTs. It has been documented that the responsiveness of human GISTs to anticancer drugs can be affected by differences in the types of c*-kit* mutations \[[@r1]\].

Although our canine patient remained in CR during the follow-up period, we decided to provide long-term administration of imatinib mesylate to prevent further recurrence. Several studies have suggested that the long-term administration of imatinib mesylate may lead to the emergence of drug-resistant clones in the treatment of advanced GISTs in humans \[[@r1], [@r8], [@r13]\]. On the other hand, Le Cesne *et al*. have advocated non-interrupted imatinib mesylate treatment for advanced human GISTs unless adverse effects are evident \[[@r10]\]. As our patient did not develop any severe adverse events during the treatment, we decided to continue the administration of imatinib mesylate.

In this case study, the administration of imatinib mesylate was found to be an effective treatment in a canine patient with GISTs that contained an exon 9 mutation in the c*-kit* gene. Molecular-targeted therapy may therefore be a promising therapeutic strategy for GISTs in dogs.
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